COVIDIN
Nasal spray against SARS-CoV-2
Covidin blocks recent immunoevasive Omicron subvariants
Comprehensive preclinical studies of Covidin (TriSb92) demonstrate Covidin's high inhibitory potency against all COVID-19 variants of concern (VOCs), exhibiting among the most potent viral inhibition against SARS-CoV-2. Patent application on Covidin TriSb92 molecule has been submitted by Pandemblock in December 2021.
TriSb92 acts specifically on the receptor-binding domain (RBD) of the viral spike protein. TriSb92 can inactivate coronavirus spike protein and offers robust and immediate protection against the virus. It potently neutralizes all known SARS-CoV-2 VOCs including the recent highly immunoevasive Omicron suvariants as evidenced using clinical virus isolates and model viruses.
The binding of TriSb92 is targeted to a highly conserved site in coronavirus spike protein that is common to all known SARS-CoV-2 variants as well as SARS-CoV-1, rendering it highly effective against a broad range of variants and related sarbecoviruses.
In animal models, nasally administered Covidin provides effective short-term protection in mice against SARS-CoV-2 infection when administered 8 h before or after viral challenge. Thus, in addition to its preventive use, intranasal administration of Covidin has therapeutic potential for treating early SARS-CoV-2 infection to prevent COVID-19.
How does it work?
A biological mask administered with a nasal spray
Covidin nasal spray acts as a biological mask in the nasal cavity protecting against SARS-CoV-2 and its variants.
Covidin (TriSb92, highlighted in blue) acts by binding to and inactivating the coronavirus spike protein (highlighted in gray), inhibiting viral entry to target cells and subsequent infection.
Who would benefit of using Covidin?
Anyone who is at risk of SARS-CoV-2 exposure.
Intranasal prophylaxis using Covidin could stop the virus before it infects enough target cells to cause a disease. Vaccinated people could take a puff of a virus-inactivating Covidin nasal spray before a high risk of exposure to protect themselves against breakthrough infection and disease. Importantly, Covidin would provide the first line of antiviral defense for vulnerable people including children, the elderly and immunocompromised persons.
The big unknown: new variants
Evidence show that both natural and vaccine-induced immunity against SARS-CoV-2 wane over time, particularly against infection. Dealing with SARS-CoV-2 continue to be globally a major public health concern and a huge burden for economy, that could be minimized using novel preventive approaches such as Covidin with a pan-neutralizing mode of action.